Susquehanna Fundamental Investments’s Rubius Therapeutics, Inc RUBY Stock Holding History

Susquehanna Fundamental Investments’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-14,550	Closed	-$355K	–	1954
2021 Q2	$355K	Sell	14,550 -1,150	-7%	-$28.8K	0.01%	1307
2021 Q1	$416K	Sell	15,700 -8,443	-35%	-$123K	0.01%	1203
2020 Q4	$183K	Sell	24,143 -9,057	-27%	-$53.8K	﹤0.01%	1364
2020 Q3	$166K	Buy	33,200 +11,800	+55%	+$62.5K	0.01%	1228
2020 Q2	$128K	Buy	+21,400	New	+$126K	0.01%	888

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Susquehanna Fundamental Investments's RUBY Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2021, closing a stake of 14,550 shares — an estimated $355K sold.

Susquehanna Fundamental Investments first reported a position in RUBY in Q2 2020 and held it in 5 quarters. The position peaked at $416K in Q1 2021. 105 funds tracked by Wall St. Rank hold RUBY as of Q3 2021.

Susquehanna Fundamental Investments reported no remaining Rubius Therapeutics, Inc position as of Q3 2021 after selling out during the quarter.
Susquehanna Fundamental Investments sold 14,550 Rubius Therapeutics, Inc shares in Q3 2021, an estimated $355K.
Susquehanna Fundamental Investments first reported a position in Rubius Therapeutics, Inc in Q2 2020 and held it in 5 quarters.
Susquehanna Fundamental Investments's Rubius Therapeutics, Inc position peaked at $416K in Q1 2021.
105 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.